Genetic Variants Associated With Development of TMD and Its Intermediate Phenotypes: The Genetic Architecture of TMD in the OPPERA Prospective Cohort Study
Key words
Cited by (0)
This work was supported by National Institutes of Health grants U01DE017018, DE016558, P01NS045685, R01DE016155, and K12DE022793. The OPPERA program also acknowledges resources specifically provided for this project by the participating institutions: Battelle Memorial Institute; University at Buffalo; University of Florida; University of Maryland; University of North Carolina at Chapel Hill. S.B.S., R.B.F. and G.D.S. are consultants and equity stock holders, and W.M. and L.D. are cofounders and equity stock holders in Algynomics, Inc, a company providing research services in personalized pain medication and diagnostics. Other authors declare no conflicts of interest.
Supplementary data accompanying this article are available online at www.jpain.org and www.sciencedirect.com.